Articles
-
Jul 21, 2023 |
hematologyadvisor.com | Ariela Katz
The BTK inhibitor pirtobrutinib recently demonstrated efficacy in a phase 1/2 trial of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously received BTK inhibitor treatment.1Now, researchers are investigating pirtobrutinib in 4 ongoing phase 3 trials.
-
Apr 14, 2023 |
hematologyadvisor.com | Ariela Katz
-
Apr 7, 2023 |
oncologynurseadvisor.com | Ariela Katz
-
Mar 31, 2023 |
hematologyadvisor.com | Ariela Katz
-
Mar 10, 2023 |
hematologyadvisor.com | Ariela Katz
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →